Protagonist Therapeutics, Inc. - stock earnings
PTGX Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 1, 2024 AfterMarket | 0.44 / 1.22 | - | - / 122.4 million | - |
PTGX Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | 27.3 million USD | 60.0 million USD |
| 2023Q3 | -34.1 million USD | ? USD |
| 2023Q2 | -38.5 million USD | ? USD |
| 2023Q1 | -31.4 million USD | ? USD |
| 2022Q4 | -31.3 million USD | ? USD |
| 2022Q3 | -30.2 million USD | ? USD |
| 2022Q2 | -40.6 million USD | 859000 USD |
| 2022Q1 | -20.7 million USD | 25.7 million USD |
| 2021Q4 | -36.9 million USD | 8.6 million USD |
| 2021Q3 | -33.8 million USD | 10.3 million USD |
| 2021Q2 | -30.8 million USD | 2.3 million USD |
| 2021Q1 | -24.0 million USD | 6.2 million USD |
| 2020Q4 | -18.9 million USD | 5.7 million USD |
| 2020Q3 | -7.8 million USD | 13.1 million USD |
| 2020Q2 | -19.4 million USD | 6.2 million USD |
| 2020Q1 | -20.1 million USD | 3.6 million USD |
| 2019Q4 | -17.5 million USD | 2.7 million USD |
| 2019Q3 | -16.4 million USD | 4.1 million USD |
| 2019Q2 | -29.2 million USD | -8.2 million USD |
| 2019Q1 | -14.1 million USD | 1.6 million USD |
| 2018Q4 | -13.9 million USD | 2.4 million USD |
| 2018Q3 | -8.7 million USD | 6.1 million USD |
| 2018Q2 | -8.7 million USD | 11.7 million USD |
| 2018Q1 | -7.7 million USD | 10.8 million USD |
| 2017Q4 | -3.1 million USD | 11.3 million USD |
| 2017Q3 | -4.8 million USD | 8.8 million USD |
| 2017Q2 | -15.0 million USD | ? USD |
| 2017Q1 | -14.1 million USD | ? USD |
| 2016Q4 | -11.2 million USD | ? USD |
| 2016Q3 | -7.1 million USD | ? USD |
| 2016Q2 | -7.1 million USD | ? USD |
| 2016Q1 | -11.7 million USD | ? USD |
| 2015Q4 | -5.5 million USD | ? USD |
| 2015Q3 | -3.4 million USD | ? USD |
| 2015Q2 | -3.2 million USD | ? USD |
| 2015Q1 | -2.7 million USD | ? USD |
| 2014Q4 | -11.1 million USD | ? USD |
PTGX Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -79.0 million USD | 60.0 million USD |
| 2022 | -123.4 million USD | 26.6 million USD |
| 2021 | -122.6 million USD | 27.4 million USD |
| 2020 | -66.2 million USD | 28.6 million USD |
| 2019 | -77.2 million USD | 231000 USD |
| 2018 | -38.9 million USD | 30.9 million USD |
| 2017 | -37.0 million USD | 20.1 million USD |
| 2016 | -37.2 million USD | ? USD |
| 2015 | -14.9 million USD | ? USD |
| 2014 | -11.1 million USD | ? USD |
PTGX
Price: $25.54
52 week price:
Earnings Per Share: -1.39 USD
P/E Ratio: -9.97
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 966400
Ebitda: -4.9 millionMarket Capitalization: 1.6 billion